News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2022 POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery Todd Neale April 02, 2022
News Conference News ACC 2021 Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC Michael O'Riordan May 17, 2021
News Conference News ACC 2020 E-Cigarettes Added to Counseling Can Help Smokers Quit at 12 Weeks Caitlin E. Cox March 31, 2020
News Opinion Editor's Corner ACC 2019 Live From New Orleans: Opening Day at ACC 2019 Shelley Wood March 16, 2019
News Conference News ACC 2018 PFO Closure Guided by High-Risk Features on Echo Shows Benefit in DEFENSE-PFO Shelley Wood March 15, 2018
News Conference News ACC 2018 PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats Yael L. Maxwell March 14, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2018 Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS Michael O'Riordan March 12, 2018
News Conference News ACC 2016 Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes Michael O'Riordan April 07, 2016
News Conference News ACC 2016 New-Generation Watchman FLX Device Pulled From European Shelves Over Embolism Concerns Todd Neale April 04, 2016
News Conference News ACC 2014 Renal Denervation Fails to Meet Efficacy Endpoints Compared with Placebo Procedure Yael L. Maxwell March 29, 2014